A reduced response to immunotherapy was suggested by a higher immune escape score, exclusion tumor mutational burden (TMB) score, lower tumor immune dysfunction, and lower immunophenoscores for programmed death 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA4) in patients with a high PRS, lower response rate, and poor prognosis [8]. This evidence concerns the gene CTLA4 and neoplasm.